Exact Therapeutics Abstract on its Phase I ACTIVATE Study to be Presented at the 2021 ASCO Annual Meeting
News provided by
Share this article
Share this article
OSLO, Norway and LONDON, May 20, 2021 /PRNewswire/ Exact Therapeutics AS (Euronext Growth: EXTX), a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT®) to harness the power of ultrasound in therapeutic amplification across multiple therapeutic areas and product classes, today announces that an abstract describing the background and methodology of its Phase I study, ACTIVATE, has been released for publication at the 2021 ASCO Annual Meeting.
The ACTIVATE Study (NCT04021277) is the first in a series of clinical investigations planned of the Company s Acoustic Cluster Therapy (ACT®) platform technology for targeted therapeutic enhancement.